查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1924696

按剂型、规格、包装、用途、通路和最终用户分類的通用名Lurasidone学名药市场—2026-2032年全球预测

Lurasidone Hydrochloride Generics Market by Form, Strength, Packaging Type, Application, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年，盐酸Lurasidone学名药市场价值为 8.9592 亿美元，预计到 2026 年将增长至 9.8524 亿美元，到 2032 年将达到 18.4048 亿美元，复合年增长率为 10.83%。

关键市场统计数据
基准年 2025 8.9592亿美元
预计年份：2026年 9.8524亿美元
预测年份 2032 1,840,480,000 美元
复合年增长率 (%) 10.83%

本文简要概述了影响盐酸鲁拉西酮Lurasidone学名药的临床应用、监管途径和商业性需求。

本执行摘要探讨了影响仿製药Lurasidone学名药市场的竞争格局和临床现状，该药物在现代精神疾病治疗策略中扮演着日益重要的角色。摘要对专利到期、监管路径和生产复杂性进行了综合分析，并将该化合物置于更广泛的情绪障碍和精神病治疗框架中。透过重点关注临床适应症、剂型、通路和终端用户趋势，概要为生产者、经销商和相关人员的策略决策提供了基础。

分析不断发展的临床证据、监管预期和生产创新如何重塑Lurasidone学名药的竞争格局

受临床需求、不断变化的监管法规和生产製程创新等因素的共同驱动，学名药的市场环境Lurasidone经历着变革性的变化。临床上，其在思觉失调症方面的确切效用，以及在重度忧郁症和躁郁症方面疗效日益增强的证据，正在改变处方模式，并促使支付方和临床医生更加严格地评估其成本效益和治疗替代性。同时，监管机构正在完善生物等效性要求和核准后药物警戒要求，这正在推动研发时间表和生命週期管理策略的调整。

需要对 2025 年关税变化及其对学名药供应链韧性筹资策略和商业营运的连锁影响进行冷静评估。

2025年公布的政策决定和关税调整为医药原料和製剂的生产商和经销商带来了新的成本和营运方面的考量。某些活性药物成分和中间体化学品的进口关税提高，加剧了依赖全球独立供应链的企业对投入成本的敏感度。为此，一些生产商正在加快供应商多元化，推进本地化筹资策略，并签订长期合同，以降低关税波动带来的风险。这些调整将影响前置作业时间、库存计划和利润管理。

深入的细分市场分析展示了临床适应症、製剂强度、通路、终端用户和包装选择对商业和营运策略的影响。

细分市场层面的差异化是理解竞争优势所在的关键，这体现在治疗领域和产品剂型两方面。在同一治疗领域内，必须牢记双极性情感障碍、重度忧郁症和思觉失调症之间的临床差异，因为这些适应症的处方习惯和报销途径截然不同。剂型的选择，例如一般片剂与口崩坏片，会影响患者的依从性和给药方式，进而影响产品在门诊和住院环境中的定位。

区域市场动态和监管差异影响市场进入和供应策略。美洲、欧洲、中东和非洲以及亚太地区的区域市场动态和监管差异会影响市场进入和供应策略。

区域趋势在商业规划和监管策略中发挥着至关重要的作用，美洲、欧洲、中东和非洲以及亚太地区呈现出截然不同的模式。在美洲，支付方结构和处方集管理实践往往侧重于成本效益和治疗替代，从而影响合约签订方式和回扣谈判。病患准入计画和与专科药局的合作也影响精神科药物的供应。各国监管机构之间的监管协调以及促进国内生产的政策，对于供应连续性和定价策略而言，正日益成为重要的考量。

公司层面的竞争和营运洞察突显了推动学名药，包括监管应对力、生产能力和分销通路伙伴关係。

製造商和商业伙伴之间的竞争地位取决于其在监管申报、生产品质和分销管道方面的能力。主要企业凭藉着完善的生物等效性文件、支援多种剂型和剂量的适应性生产工艺，以及与经销商建立的策略联盟（确保产品进入医院、零售药局和线上药局），从而脱颖而出。投资于病患支援服务、依从性计画和临床医生教育的企业，能够创造价格之外的显着价值，这在竞争性竞标和处方集评估中日益重要。

为製造商和经销商提供切实可行的策略建议，重点关注强有力的采购、基于证据的合作以及针对特定管道的商业化，以最大限度地发挥影响力。

寻求可持续竞争优势的行业领导者应专注于三个相互关联的优先事项：增强供应链韧性、深化与临床试验机构和支付方的合作以及针对特定管道的商业化。透过建立多通路关键物料来源、策略性库存缓衝以及检验的二级供应商来强化供应链，可以降低受关税衝击和物流中断的影响。同时，投资于全面的监管计划和健全的生物等效性项目，可以加快核准流程，并有助于产品进入具有不同证据要件的市场。

对多源研究途径的透明解释：结合相关人员访谈、监管审查和管道分析，检验研究结果和见解。

本研究整合了透过相关人员访谈、监管审查和管道分析收集的一手和二手讯息，全面展现了Lurasidone学名药的市场格局。一手资讯包括对临床医生、药剂师和供应链专家的结构化访谈，旨在了解处方行为、配药模式和采购机制。二手资讯包括监管指导文件、已发表的临床证据和公共政策声明，以阐明监管和报销背景，并确保结论符合现行标准。

一项严谨的审查，重申了关键的临床、监管和营运重点以及实现持续商业性成功的策略路径。

总之，Lurasidone学名药仿製药的竞争格局是由临床差异、监管严格性和营运复杂性共同塑造的。在双极性情感障碍、重度忧郁症和思觉失调症等适应症中，临床差异化需要与处方医生进行有针对性的沟通，并提供个人化的证据资讯。生物等效性和上市后监测的监管要求需要谨慎用药和药物警戒，而灵活的剂型和剂量生产能力则有助于应对力。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 盐酸Lurasidone学名药市场按剂型划分

  • 口溶锭
  • 药片

9. 盐酸Lurasidone学名药市场（依规格划分）

  • 20 mg
  • 40mg
  • 60mg
  • 80mg

第十章 盐酸Lurasidone酮学名药市场（以包装形式划分）

  • 泡壳包装
  • 瓶子

第十一章 按应用分類的通用Lurasidone学名药市场

  • 双相情感障碍相关的忧郁症
  • 重度忧郁症
  • 思觉失调症

第十二章 盐酸Lurasidone学名药市场（依通路划分）

  • 离线
  • 在线的

第十三章 盐酸Lurasidone学名药市场（依最终用户划分）

  • 诊所
  • 居家照护设施
  • 医院

第十四章 各地区Lurasidone酮学名药市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十五章 盐酸Lurasidone学名药市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十六章 各国Lurasidone酮学名药市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

17. 美国通用Lurasidone学名药市场

第十八章：中国仿製学名药Lurasidone酮市场

第十九章 竞争情势

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Accord Healthcare
  • Alembic Pharmaceuticals
  • Alkem Laboratories
  • Amneal Pharmaceuticals
  • Annora Pharma
  • Aurobindo Pharma
  • Camber Pharmaceuticals
  • Chartwell Rx
  • Cipla
  • Dr. Reddy's Laboratories
  • Emcure Pharmaceuticals
  • Heritage Pharma Avet
  • Icon Life Sciences
  • Intas Pharmaceuticals
  • Invagen Pharmaceuticals
  • Jubilant Generics
  • Linux Laboratories
  • Lupin
  • Macleods Pharmaceuticals
  • MSN Laboratories
  • Sun Pharmaceutical Industries
  • Teva Pharmaceutical Industries
  • Torrent Pharmaceuticals
  • Zydus Pharmaceuticals
Product Code: MRR-7A380DA7C432

The Lurasidone Hydrochloride Generics Market was valued at USD 895.92 million in 2025 and is projected to grow to USD 985.24 million in 2026, with a CAGR of 10.83%, reaching USD 1,840.48 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 895.92 million
Estimated Year [2026] USD 985.24 million
Forecast Year [2032] USD 1,840.48 million
CAGR (%) 10.83%

A concise orienting overview that frames clinical uses regulatory pathways and commercial imperatives shaping the lurasidone hydrochloride generics environment

This executive summary introduces the competitive and clinical landscape shaping lurasidone hydrochloride generics, a category increasingly central to modern psychiatric therapeutic strategies. The narrative synthesizes patent expirations, regulatory pathways, and manufacturing complexity while situating the compound within broader treatment paradigms for mood and psychotic disorders. By focusing on clinical indications, dosage formulations, distribution channels, and end-user patterns, the introduction sets the stage for strategic decision-making by manufacturers, distributors, and clinical stakeholders.

Beyond basic characterization, the introduction emphasizes how evolving prescriber preferences and payer frameworks influence generic adoption. It highlights the importance of quality-by-design in manufacturing, the role of bioequivalence studies in regulatory approvals, and the operational considerations around packaging and distribution. The aim is to provide an accessible yet rigorous foundation that enables readers to navigate subsequent sections with a clear understanding of the key drivers, constraints, and opportunities that define the current generics environment for lurasidone hydrochloride.

An analysis of how evolving clinical evidence regulatory expectations and manufacturing innovations are reshaping the competitive dynamics of lurasidone generics

The lurasidone generics landscape is undergoing transformative shifts driven by convergence of clinical demand, regulatory evolution, and manufacturing innovation. Clinically, expanded evidence for efficacy in major depressive disorder and bipolar depression alongside established utility in schizophrenia has altered prescribing patterns, prompting payers and clinicians to evaluate cost-effectiveness and therapeutic interchangeability more closely. Concurrently, regulatory authorities are refining bioequivalence expectations and post-approval pharmacovigilance requirements, which is reshaping development timelines and lifecycle management strategies.

On the supply side, advancements in formulation science, particularly in orally disintegrating tablet technologies, are enabling competitive differentiation even within a generics marketplace. Parallel improvements in contract manufacturing and supply chain digitization are reducing lead times and improving traceability, yet they also expose manufacturers to geopolitical and input-cost volatility. Taken together, these shifts are driving manufacturers to prioritize robust regulatory dossiers, scalable quality systems, and channel-specific commercialization plans that account for both clinical nuance and operational resilience.

A clear-eyed assessment of the 2025 tariff changes and their cascading effects on supply chain resilience sourcing strategies and commercial operations for generics

Policy decisions and tariff adjustments announced in 2025 have introduced new cost and operational considerations for manufacturers and distributors of pharmaceutical ingredients and finished dosage forms. Increased import duties on select active pharmaceutical ingredients and intermediate chemicals have raised input-cost sensitivity for companies that rely on globalized supply chains. In response, several manufacturers have accelerated supplier diversification, localized sourcing strategies, and long-term contracting to mitigate exposure to ad hoc tariff fluctuations. These adjustments have implications for lead times, inventory planning, and margin management.

In parallel, logistics and customs processing times have become a focal point for commercial planning as companies seek to avoid bottlenecks that exacerbate cost pressures. Regulatory agencies and industry associations have responded by emphasizing transparency in supply chains and by encouraging pre-clearance and tariff classification alignment to reduce clearance delays. The net effect of these tariff-related developments is not uniform across the sector; enterprises with integrated manufacturing capabilities and flexible sourcing are better positioned to absorb incremental costs, while smaller players are exploring partnerships and contract manufacturing arrangements to stabilize supply and preserve competitive pricing.

Insightful segmentation analysis demonstrating how clinical indications formulations strengths channels end-users and packaging choices influence commercial and operational strategy

Segment-level distinctions are central to understanding where competitive advantage can be established across therapeutic application and product presentation. Within therapeutic application, attention must be paid to clinical differentiation across bipolar depression, major depressive disorder, and schizophrenia because prescribing routines and reimbursement pathways vary significantly among these indications. Formulation choices such as standard tablets versus orally disintegrating tablets introduce different patient adherence and administration considerations, which in turn affect product positioning for outpatient and institutional use.

Strength variations spanning 20 mg, 40 mg, 60 mg, and 80 mg require manufacturers to plan manufacturing flexibility and inventory strategies that can accommodate dose titration and switching. Distribution channel complexity encompasses hospital pharmacy settings-both general pharmacies and psychiatric units-online pharmacy models that include proprietary and third-party platforms, and retail outlets divided between chain and independent pharmacies; each channel has distinct procurement cycles, margin expectations, and promotional levers. End-user segmentation across clinics with day care and outpatient models, home care settings that rely on caregiver or self-administration, and hospitals differentiated by general and psychiatric facilities informs outreach, packaging, and patient support strategies. Packaging type choices between blister and bottle affect stability, dispensing accuracy, and patient convenience, and therefore should be aligned with channel and end-user preferences to optimize uptake and adherence.

Regional market dynamics and regulatory nuances across the Americas Europe Middle East & Africa and Asia-Pacific that influence market access and supply strategies

Regional dynamics play a decisive role in commercial planning and regulatory strategy, with distinctive patterns emerging across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, payer structures and formulary management practices tend to emphasize cost-effectiveness and therapeutic substitution, influencing contracting approaches and rebate negotiation; patient access programs and specialty pharmacy partnerships also shape uptake for psychiatric therapies. Regulatory harmonization between national authorities and incentivized domestic manufacturing initiatives are increasingly relevant considerations for supply continuity and pricing strategy.

In Europe Middle East & Africa, diverse regulatory regimes and varying levels of healthcare infrastructure create a mosaic of market access pathways. Centralized regulatory procedures in some jurisdictions coexist with country-level reimbursement decisions, prompting tailored dossiers and localized HEOR narratives. In the Asia-Pacific region, rapid growth in outpatient care and expanding digital pharmacy ecosystems are changing distribution models, while regional manufacturing capabilities and supply integration present both opportunities for cost optimization and risks tied to raw material sourcing. Navigating these regional idiosyncrasies requires calibrated market-entry strategies and adaptive channel management.

Competitive and operational company-level observations highlighting regulatory strengths manufacturing capabilities and channel partnerships that drive differentiation in generics

Competitive positioning among manufacturers and commercial partners hinges on capabilities across regulatory filings, manufacturing quality, and channel distribution. Leading companies differentiate through robust bioequivalence dossiers, adaptive manufacturing processes that support multiple strengths and formulations, and strategic alliances with distributors that secure hospital, retail, and online pharmacy placements. Firms that invest in patient support services, adherence programs, and clinician education can create perceptible value beyond price, which is increasingly important in competitive tenders and formulary evaluations.

Moreover, organizations that can integrate pharmacovigilance feedback with post-market evidence collection are better positioned to sustain trust among prescribers and payers. Contract manufacturing organizations that offer scalable capacity and regulatory-compliant facilities are strategic partners for companies that lack vertically integrated production. Finally, partnerships that enable streamlined supply to psychiatric units and specialized clinics, as well as digital-first distribution agreements with proprietary and third-party online pharmacies, amplify reach and responsiveness to evolving clinical and channel demand.

Actionable strategic recommendations for manufacturers and distributors focusing on resilient sourcing evidence-driven engagement and channel-tailored commercialization to maximize impact

Industry leaders seeking durable advantage should focus on three interlocking priorities: supply chain resilience, clinical and payer engagement, and channel-specific commercialization. Strengthening supply chains through multi-sourcing of critical inputs, strategic inventory buffers, and validated secondary suppliers reduces vulnerability to tariff shocks and logistical disruption. Concurrently, investing in comprehensive regulatory planning and robust bioequivalence programs will accelerate approvals and facilitate market entry across jurisdictions with varying evidentiary expectations.

On the commercial front, tailored engagements with clinicians and payers that emphasize real-world adherence benefits, comparative tolerability data, and support services can shift procurement decisions beyond unit price. Channel strategies must be granular, recognizing the differing needs of hospital pharmacy settings including psychiatric units, online pharmacy platforms whether proprietary or third-party, and retail environments across chain and independent pharmacies. Finally, consider packaging and patient-support innovations that align with end-user realities in clinics, home care settings, and hospitals to improve adherence and clinical outcomes while enhancing product differentiation.

Transparent explanation of the multi-source research approach combining stakeholder interviews regulatory review and channel analysis to validate findings and insights

This research synthesizes primary and secondary intelligence gathered through stakeholder interviews, regulatory review, and channel analyses to produce a holistic view of the lurasidone generics environment. Primary inputs included structured interviews with clinicians, pharmacists, and supply chain specialists to capture prescriber behavior, dispensing patterns, and procurement mechanics. Secondary inputs comprised regulatory guidance documentation, published clinical evidence, and public policy statements to inform regulatory and reimbursement context while ensuring that conclusions are consistent with current standards.

Analytical methods emphasized cross-validation of findings across sources and triangulation between clinical practice insights and distribution behavior. Quality controls included validation of clinical claims against peer-reviewed literature and verification of distribution patterns through interviews with pharmacy operations personnel. The methodological approach prioritized transparency in assumptions and clear documentation of data sources and limitations, thereby enabling readers to assess the robustness of conclusions and to replicate key analytic steps for localized decision-making.

A rigorous concluding synthesis that reiterates clinical regulatory and operational imperatives and the strategic pathways to sustained commercial success

In conclusion, the competitive landscape for lurasidone hydrochloride generics is shaped by a confluence of clinical nuance, regulatory rigor, and operational complexity. Clinical differentiation across indications such as bipolar depression major depressive disorder and schizophrenia requires targeted engagement with prescribers and tailored evidence communication. Regulatory expectations for bioequivalence and post-market surveillance necessitate careful dossier preparation and pharmacovigilance readiness, while manufacturing flexibility across strengths and formulation types supports responsiveness to clinical dosing patterns.

Distribution and end-user segmentation-from hospital pharmacies and psychiatric units to online and retail channels and from clinics to home care settings-requires channel-specific strategies that align packaging, support services, and inventory practices with actual dispensing and administration contexts. Strategic investments in supply chain resilience and partnerships that bridge manufacturing, clinical outreach, and digital distribution will be decisive for organizations aiming to secure trusted positions within this evolving generics market.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Lurasidone Hydrochloride Generics Market, by Form

  • 8.1. Orally Disintegrating Tablet
  • 8.2. Tablet

9. Lurasidone Hydrochloride Generics Market, by Strength

  • 9.1. 20 mg
  • 9.2. 40 mg
  • 9.3. 60 mg
  • 9.4. 80 mg

10. Lurasidone Hydrochloride Generics Market, by Packaging Type

  • 10.1. Blister
  • 10.2. Bottle

11. Lurasidone Hydrochloride Generics Market, by Application

  • 11.1. Bipolar Depression
  • 11.2. Major Depressive Disorder
  • 11.3. Schizophrenia

12. Lurasidone Hydrochloride Generics Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Lurasidone Hydrochloride Generics Market, by End User

  • 13.1. Clinics
  • 13.2. Home Care Settings
  • 13.3. Hospitals

14. Lurasidone Hydrochloride Generics Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Lurasidone Hydrochloride Generics Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Lurasidone Hydrochloride Generics Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Lurasidone Hydrochloride Generics Market

18. China Lurasidone Hydrochloride Generics Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Accord Healthcare
  • 19.6. Alembic Pharmaceuticals
  • 19.7. Alkem Laboratories
  • 19.8. Amneal Pharmaceuticals
  • 19.9. Annora Pharma
  • 19.10. Aurobindo Pharma
  • 19.11. Camber Pharmaceuticals
  • 19.12. Chartwell Rx
  • 19.13. Cipla
  • 19.14. Dr. Reddy's Laboratories
  • 19.15. Emcure Pharmaceuticals
  • 19.16. Heritage Pharma Avet
  • 19.17. Icon Life Sciences
  • 19.18. Intas Pharmaceuticals
  • 19.19. Invagen Pharmaceuticals
  • 19.20. Jubilant Generics
  • 19.21. Linux Laboratories
  • 19.22. Lupin
  • 19.23. Macleods Pharmaceuticals
  • 19.24. MSN Laboratories
  • 19.25. Sun Pharmaceutical Industries
  • 19.26. Teva Pharmaceutical Industries
  • 19.27. Torrent Pharmaceuticals
  • 19.28. Zydus Pharmaceuticals

LIST OF FIGURES

  • FIGURE 1. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY ORALLY DISINTEGRATING TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY ORALLY DISINTEGRATING TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY ORALLY DISINTEGRATING TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY 20 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY 20 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY 20 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY 40 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY 40 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY 40 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY 60 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY 60 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY 60 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY 80 MG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY 80 MG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY 80 MG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY BLISTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY BLISTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY BLISTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY BOTTLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY BOTTLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY BOTTLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY BIPOLAR DEPRESSION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY BIPOLAR DEPRESSION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY BIPOLAR DEPRESSION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY MAJOR DEPRESSIVE DISORDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY SCHIZOPHRENIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY SCHIZOPHRENIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY SCHIZOPHRENIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. AMERICAS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 58. AMERICAS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 64. NORTH AMERICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. ASEAN LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. GCC LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GCC LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 123. GCC LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 124. GCC LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. GCC LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 126. GCC LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 127. GCC LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPEAN UNION LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPEAN UNION LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. BRICS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. BRICS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 142. G7 LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 143. G7 LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 144. G7 LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 145. G7 LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. G7 LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 147. G7 LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 148. G7 LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 149. NATO LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 150. NATO LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 151. NATO LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 152. NATO LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. NATO LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 154. NATO LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. NATO LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. GLOBAL LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 159. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 161. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 162. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. CHINA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 165. CHINA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 166. CHINA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY STRENGTH, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. CHINA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 169. CHINA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA LURASIDONE HYDROCHLORIDE GENERICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)